Navigation Links
Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement
Date:6/30/2009

avity I.V. equipment to our existing portfolio provides additional options for our members as part of our flexible, customer-driven approach to reducing supply expenses for our members."

About MedAssets

MedAssets (Nasdaq: MDAS) partners with healthcare providers to improve their financial strength by implementing spend management and revenue cycle solutions that help control cost, improve margins and cash flow, increase regulatory compliance, and optimize operational efficiency. MedAssets serves more than 125 health systems, 3,300 hospitals and 30,000 non-acute care healthcare providers. For more information, visit www.medassets.com.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Hospira Receives Favorable Court Decision on Eloxatin(R)
2. Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies
3. Hospira Names Brian Meadows Supply Chain Chief
4. Hospira Supports Newly Introduced Biogenerics Legislation
5. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
6. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
7. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
8. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
9. Hospira Expands Board of Directors
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Biogenerics Will Save Billions, Says Hospira CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)The Scientist, a leading scientific magazine covering the life sciences, ranked Photometrics’ Evolve “Intelligent” EMCCD camera fourth among the publication’s “Top 10 Inn
Breaking Biology Technology:Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
...p and commercialize small-molecule ...und AEG40826 works synergistically with HGS TRAIL ...tivity of both drugs -, - IAP inhibitors also sh... anti- cancer agents across broad range of ca.... 20 ,Human Genome Sciences, Inc. (Nasdaq: HGSI )...
...ences, Inc. (Nasdaq: HGSI ) today announced that ...icensing and collaboration agreement with,Aegera T...econd randomized,Phase 2 trial of HGS-ETR1 in comb...wscom.com/cgi-bin/prnh/20010612/HGSLOGO ), This ...t and will be,held today, Thursday, December 20, 2...
... in your computer is there to keep the microproces...nent materials start to expand, inducing cracks th...dentally, ruin the chip. Thermal expansion can als...rate, reduce performance through changes in the el...icate structures that emit laser light. , Recentl...
Other Biology Technology:Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 2Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 3Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 4Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 5Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 6Human Genome Sciences to Sponsor Conference Call 2'Hybrid' semiconductors show zero thermal expansion; Could lead to hardier electronics 2
(Date:12/4/2009)By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/4/2009)Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of h
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2How to read brain activity? 2U-Iowa study helps advance heart-related research 2For Older Walkers Faster Is Better 61159 1The New Pollutants Brewing in Our Water 61157 1The New Pollutants Brewing in Our Water 61157 2The New Pollutants Brewing in Our Water 61157 3The New Pollutants Brewing in Our Water 61157 4Uninsured Issue Takes Center Stage This Weekend in New Orleans 61155 1
...tober 2008 The European Molecular Biology Organiz... EMBO Molecular Medicine , a new journal dedicate...e between molecular biology and clinical research....original research offering molecular insights into...d human diseases as well as potential clinical app...
...nvestigating the rice genome has been developed by...fessor of plant pathology. The inexpensive, public... the 45,000 genes in the rice genome. Details are ...oS ONE . , In higher organisms, such as humans or...es at different times. Scientists have developed h...
...e of the virus, known as Seneca Valley Virus-001, ...f the Picornaviridae viral family, and confirms it...rus." The new study reveals that the virus,s outer...th uneven divets and raised spikesand the RNA stra...ike a whiffleball. , "It is not at all like other...
Other Biology News:Scripps research team solves structure of 'beneficial' virus 2
Rabbit Anti-Human acetyl-Histone H3 (Lys 4) Antibody, Unconjugated from Upstate
Anti-gp64 Antibody, Unconjugated from Novagen
Mouse Anti-Mouse Ly 6C.2(Ly 28.2) Monoclonal Antibody, Unconjugated, Clone 5075-3.6 from CEDARLANE Laboratories Limited
Rabbit Anti-b-Catenin, phospho (Ser675) Antibody, Unconjugated from Spring Bioscience
Biology Products: